A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.

The restructured biotech’s new lead project enters phase 1.

But neladalkib results worsen, and come with a red flag about liver enzyme elevations.

The private biotech adds another asset to J&J’s prostate cancer pipeline.

The company will imminently start its third pivotal trial of PF-08634404.

The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.